Tag Archives: Eli Lilly

FDA Approves New Alzheimer’s Drug That Slows Memory Loss – National

The U.S. Food and Drug Administration on Tuesday approved Eli Lilly’s treatment for early-stage Alzheimer’s disease, the second therapy to slow the progression of the brain disease to become available to U.S. patients. The approval for donanemab, which will be sold under the brand name Kisunla, followed recommendations from the agency’s outside experts who unanimously supported its use in patients …

Read More »